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ABSTRACT Antisense oligonucleotides present a powerful means to inhibit expression of speciﬁc genes, but their
effectiveness is limited by factors including cellular delivery, biochemical attack, and poor binding to target. We have developed
a systems model of the processes required for an antisense oligonucleotide to enter, gain access to its target mRNA, and exert
activity in a cell. The model accurately mimics observed trends in antisense effectiveness with the stability of the oligonucleotide
backbone and with the afﬁnity/kinetics of binding to the mRNA over the time course of inhibition. By varying the model param-
eters within the physically realizable range, we note that the major molecular and cellular barriers to antisense effectiveness are
intracellular trafﬁcking, oligonucleotide-mRNA binding rate, and nuclease degradation of oligonucleotides, with a weaker
dependence on total cellular uptake than might be expected. Furthermore, the model may serve as a predictive tool to design
and test strategies for the cellular use of antisense oligonucleotides. The use of integrated mathematical modeling can play a
signiﬁcant role in the development of antisense and related technologies.
INTRODUCTION
Antisense oligonucleotides (AS ONs) are being developed
clinically for applications in combating viral diseases, can-
cer, and inﬂammation (1). In addition, their ability to serve
as transient ‘‘knockdowns’’ of gene expression is being
exploited to study gene function and has been proposed as
a strategy for systematic use in functional genomics (2,3).
However, technical challenges have limited the widespread
application of this approach to date. These include the selec-
tion of antisense sequences and structures with high afﬁnity
for their target, the tendency of oligonucleotides to be de-
graded by nucleases in cells and in serum, and the delivery of
biologically effective doses in a speciﬁc and nontoxic fash-
ion (4). In addition, the physical properties of the ON (and
any delivery vectors) and several cellular variables affect the
activity of AS ONs. These include the ability of the ONs to
escape endosomes, the rate of ribonuclease H (Rnase H)
cleavage within the cells, and the expression level of the
particular mRNA being targeted. The molecular design of
oligonucleotides with properties tailored to overcome one of
these limitations (e.g., phosphorothioate (PS) backbone mod-
iﬁcation for enhanced stability) often results in a trade-off
whereby other properties of the AS ON are compromised
(e.g., binding afﬁnity for target and increased propensity for
protein binding by PS ONs).
We present an integrated framework for understanding
and improving the effectiveness of AS ONs based on mathe-
matical modeling of the cellular events that an AS ON
undergoes as it attempts to reach and block the target. A few
mathematical models have been developed previously to
describe antisense activity under steady-state (5,6) and dy-
namic (7) conditions. These models are based on mass action
kinetic balances as ONs move through extracellular and
intracellular compartments, and our work builds upon these
studies. In particular, we consider a greater number of com-
partments (bulk solution, cell surface, endosomal, and cy-
toplasmic) and ON states (e.g., adsorbed to cell surfaces,
hybridized to target species, hybridized to nontarget species).
Our goal is to determine those molecular design variables
that can be manipulated to produce more effective AS ONs
and to provide new insights for the timescales and conditions
necessary for successful antisense effects.
MATERIALS AND METHODS
Systems model of oligonucleotide uptake,
trafﬁcking, and binding
The model consists of a set of mass action kinetic equations organized into
three modules: cellular uptake, endocytosis and trafﬁcking, and hybridiza-
tion and catalysis. Except for the bulk concentration of oligonucleotide
(Ab, in mM), concentrations are expressed as #/cell, and time is expressed in
minutes. Transport between cellular compartments is assumed to occur via
ﬁrst-order processes in the concentration of the species in the upstream
compartment. Binding and catalytic events are assumed to occur in accord-
ance with their reaction stoichiometry. The binding and reaction steps,
variables, and key parameters are depicted in Fig. 1.
Uptake
An oligonucleotide (or a ligand carrying an oligonucleotide) (Ab) binds to a
receptor (R) on the cell surface, and the resulting complex (Cs) is intern-
alized. It is also possible for the oligonucleotide to dissociate from the
receptor. The second-order rate constant for oligonucleotide-receptor
binding is k1, the ﬁrst-order rate constant for dissociation is k1, and the
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ﬁrst-order rate constant for internalization is ki. In addition, degradation of
bulk oligonucleotide occurs via ﬁrst-order decay (with rate constant db). The
phase ratio, f, serves as a conversion factor between bulk solution con-
centration (in mM) and cellular concentration (molecules/cell):
dAb
dt
¼ fðk1AbR1 k1CsÞ  dbAb (1)
dCs
dt
¼ k1AbR ðk11 kiÞCs: (2)
Endocytosis and trafﬁcking
Once the complex is internalized via endocytosis, the receptor dissociates to
form an internalized receptor (Ri), which is capable of recycling (with rate
constant kr) to the cell surface. The internalized oligonucleotide (Ai) is either
routed for degradation (with rate constant di) or escapes into the cytoplasm
(with rate constant kt) to form cytoplasmic oligonucleotide (Ac):
dR
dt
¼ k1AbR1 k1Cs1 k rRi (3)
dAi
dt
¼ kiCs  ðkt1 diÞAi (4)
dRi
dt
¼ kiCs  krRi: (5)
Binding and catalysis
A cytoplasmic oligonucleotide may hybridize to either its target mRNA (M)
or possibly to a nontarget mRNA (N) to form target (D) and nontarget (E)
duplexes, respectively. The rate constant for association to target mRNA is
ka and to nontarget mRNA is k9a. Duplexes of ON-mRNA are recognized by
Rnase H, which cleaves the RNA portion of the duplex to produce degraded
target or nontarget mRNA. Because the amount of substrate (i.e., duplex)
available for Rnase H is likely to be signiﬁcantly smaller than the Michaelis
constant of 0.2 mM (8), Michaelis-Menten kinetics reduces to a pseudo-ﬁrst-
order expression with rate constant veff, assumed to be identical for target
and nontarget duplexes. The oligonucleotide is released intact after mRNA
degradation and is available for further hybridization events. Because
nontarget mRNA is far in excess to target mRNA, the total concentration of
nontarget mRNA can be taken as a constant, N0. Although there are many
possible nontarget mRNAs, they are lumped together as a single entity. The
presence or absence of nontarget mRNA did not exert a substantial effect on
model results. In competition with these hybridization events, oligonucle-
otide is degraded by cellular nucleases (with rate constant dc). In addition to
antisense-mediated degradation, the target mRNA undergoes constitutive
synthesis (with constant rate sm) and degradation (with ﬁrst-order rate
constant dm)
dAc
dt
¼ ktAikaAcMk9a AcN01kdD1k9dE1veffðD1EÞdcAc
(6)
dM
dt
¼ sm  kaAcM1 kdD dmM (7)
dD
dt
¼ kaAcM  ðkd1 veffÞD (8)
dC
dt
¼ k9aAcN0  ðkd1 veffÞC: (9)
Applicable ranges for parameter values were determined from the literature
and/or our own measurements (Table 1). The equations were solved
numerically using the ode15s solver for stiff differential equations in
MATLAB 6.1 (The MathWorks, Natick, MA).
Experimental determination of uptake and
activity in CHO cells
CHO-K1 cells (ATCC, Manassas, VA) were stably transfected with the
pd1EGFP plasmid by a protocol consisting of 4 h transfection in serum-free
medium with Lipofectamine 2000 (Invitrogen, Carlsbad, CA), followed by
selection in medium containing serum and G418 (Sigma, St. Louis, MO),
clonal dilution, expansion, and ﬂow cytometric analysis (Barnes et al.,
unpublished). An AS ON effective against pd1EGFP in this cell line was
identiﬁed by screening a number of candidates (B. M. Dunham, L. K. Lee,
Z. Li, and C. M. Roth, unpublished). A modiﬁed form of this PS
oligonucleotide with the Alexa647 ﬂuorophore conjugated at the 59-end
(A-ODN157) was purchased from Integrated DNA Technologies (Coral-
ville, IA). In addition, the identical sequence was obtained without the
ﬂuorescent tag (ODN157), as well as a tagged, scrambled ON sequence
(A-ODNcontrol).
FIGURE 1 Schematic diagram of major interactions
in the model for antisense delivery and activity. AS
ONs (shown in red throughout) in the extracellular
environment (Ab) bind to cellular surface molecules (R)
and are internalized by endocytosis. The oligonucleo-
tides that are internalized (Ai) must escape the endo-
some to enter the cytoplasm (Ac) before routing and
degradation in lysosomes (X). Once in the cytoplasm,
AS ONs can ﬁnd their complementary target mRNA
(M) and hybridize to form a duplex (D). The duplex is
incapable of translation, and the mRNA portion may be
degraded by Rnase H. Hybridization of cytoplasmic
oligonucleotides to nontarget mRNA (N) is also pos-
sible, and these duplexes would also serve as substrates
for Rnase H. Deﬁnition of all variables can be found in
the main text.
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Each oligonucleotide was combined with Lipofectamine 2000 at a weight
ratio of 2.5 (Lipofectamine/ON) at an ON concentration of 100 nM and
incubated with the CHO-pd1EGFP cells for varying durations. At each time,
replicate wells of cells were washed, trypinized, pelleted by centrifugation,
suspended in phosphate-buffered saline maintained on ice, and subjected as
quickly as possible to ﬂow cytometry. Forward and side scatter character-
istics were used to remove dead cells from the analysis, and the remaining
cells were analyzed for Alexa uptake and pd1EGFP inhibition. Each was
determined from the geometric mean of the ﬂuorescence intensity for its
channel, with pd1EGFP values normalized to those for untreated pd1EGFP
cells.
Experimental measurement of gene expression
dynamics in H35 cells
Antisense inhibition experiments against gp130 were performed with H35
rat hepatoma cells in 24 well plates under serum-free conditions as pre-
viously described (9).
RESULTS
We have developed an integrated mathematical model of
the cellular events encountered by an AS ON to provide a
framework for interpreting quantitative molecular and cel-
lular measurements and to evaluate strategies for improving
the success of AS ONs. The AS ONs, cellular uptake recep-
tors and target and nontarget mRNAs are tracked through
various cellular locations and molecular states via mass con-
servation equations (Fig. 1).
Cellular uptake and trafﬁcking of oligonucleotides
It is commonly believed that the uptake of DNA by cells is
low due to the electrostatic repulsion between the anionic
charges residing on DNA and those residing on cell mem-
branes from their glycocalyces and phospholipids mem-
branes. ONs, however, are small enough to ﬁnd local regions
on cell surface proteins (which may be cationic) to which
favorable binding occurs, followed by adsorptive endocyto-
sis. As a result, signiﬁcant quantities of ONs are delivered
to cells, and reasonably accurate measurements of uptake are
available from radiolabel measurements (10–12). Indeed,
these studies have demonstrated that signiﬁcant quantities
of oligonucleotides are taken up by cells, much more than
would be required for stoichiometric inhibition of target
mRNAs expressed on the levels of hundreds to thousands per
cell. Although there is not a receptor with a known functional
role in mediating ON uptake, cell membrane proteins have
been identiﬁed as mediating uptake via adsorptive endocy-
tosis, resulting in saturation of uptake at moderate ON con-
centrations (a nonsaturating component of uptake, believed
to be mediated by ﬂuid-phase endocytosis, has also been
observed at high ON concentrations) (10–13).
Given that over the course of a few hours, hundreds of
thousands of oligonucleotides can enter a cell, what is their
fate? After internalization, oligonucleotides must escape
vesicular compartments, avoid degradation and efﬂux, ﬁnd
their complementary target mRNA, hybridize, and remain
associated long enough to mediate Rnase H-catalyzed
destruction of the target mRNA or to inhibit translation
sterically. The intracellular trafﬁcking characteristics are
the most difﬁcult to quantify experimentally, but sufﬁcient
studies on the endosomal escape of oligonucleotides and the
dynamics of endosomal and lysosomal progression permit
order-of-magnitude estimation of their rates (14,15) (Table
1). After internalization by endosomes, oligonucleotides may
either be routed to lysosomes or achieve escape into the
cytoplasm. Signiﬁcant endosomal concentrations are reached
rapidly, peaking at 30 min (results not shown), and the levels
of cytoplasmic oligonucleotide peak later, in the range
TABLE 1 Values of model parameters
Parameter Meaning Base value References
k1 Adsorption of antisense to receptor (saturable) 0.15 mM
1 min1 (10,12)
k1 Desorption of antisense from receptor 0.03 min
1 (11)
ki Internalization 0.03 min
1 (11)
kr Recycling of receptors 0.06 min
1 (42)
kt Trafﬁcking to mRNA locale (cytoplasm) 0.003 min
1 (11)
ka Antisense-mRNA association (target) 0.1–10 mM
1 min1 (17)
kd Antisense-mRNA dissociation (target) 0.001 min
1 (17)
k9a Antisense-nontarget association 10
3 mM1 min1 Estimated
k9d Antisense-nontarget dissociation 0.001 min
1 (17)
veff RNase H cleavage 0.003 min
1 (17)
sm mRNA synthesis rate 15 cell
1 min1 (20)
dm Natural decay of target mRNA 0.03 min
1 (20,28)
db Decay of antisense in bulk 0.003 min
1 (11,16)
di Degradation or efﬂux of internalized antisense 0.06 min
1 (11,43)
dc Decay of antisense in cytoplasm 0.12 min
1 (11,16)
Ab0 Initial bulk concentration 600 nM Chosen
R0 Free receptors on surface 1 3 10
5 cell1 (10,12,44)
M0 Target mRNA 500 cell
1 (20,28)
N0 Nontarget mRNA 7 3 10
6 cell1 (20)
f Extracellular phase ratio 5 3 109 cell mM molecule1 Estimated
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330–360 min (Fig. 2 A). Because of the saturable nature of
receptor-mediated internalization, the maximum level of ON
in the cytoplasm varies by a little over twofold as the bulk ON
concentration increases ﬁvefold (Fig. 2 A). In contrast, the
maximum endosomal and cytoplasmic levels are much more
sensitive to the rates of lysosomal routing versus cytoplasmic
escape. Speciﬁcally, increased endosomal escape leads to
a dramatic increase in the cytoplasmic level of oligonucleo-
tide (Fig. 2 B), whereas increased lysosomal routing causes
a reciprocal decrease in the cytoplasmic level of oligonucle-
otide (results not shown). However, the time at which
maximal cytoplasmic concentration is reached is relatively
insensitive to the values of these parameters. Thus, from the
parameter variations associated with uptake and trafﬁcking,
the escape from endosomes before lysosomal routing and
degradation appears to be the critical step in achieving high
levels of oligonucleotide in the cytoplasm.
DNA-RNA hybridization and mRNA cleavage
After escape from endosomes, cytoplasmic oligonucleotides
are free to ﬁnd and associate with their target mRNA, and
oligonucleotide-mRNA duplexes may be subsequently de-
graded by Rnase H. Because ONs bound to mRNA are
presumably protected themselves from nuclease digestion,
the model predicts that slightly greater and longer-lasting ON
presence in the cytoplasm will result for a complementary as
opposed to noncomplementary ON (Fig. 3 A). To test this
prediction, we delivered Alexa647-tagged ONs of both com-
plementary (versus pd1EGFP mRNA and termed A-ON157)
and noncomplementary (a scrambled permutation of
A-ON157 termed A-ODNcontrol) sequences to pd1EGFP-
CHO-K1 cells using the commercial reagent, Lipofectamine
2000. We indeed found a modest extended delivery proﬁle
of the complementary ON as opposed to noncomplementary
ON (Fig. 3 B), in excellent agreement with the model.
Furthermore, the model predicts accurately the dynamics of
the uptake. It should be noted that the model parameters in
Fig. 3 A are the same as those in the base case except that the
intracellular degradation rate was reduced from 0.012 min1
to 0.003 min1. The time course of pd1EGFP inhibition
by the Alexa-labeled ON-157 was also monitored by ﬂow
cytometry. The time course is very consistent with the model
predictions, again using base case parameters and a degrada-
tion rate of 0.003 min1 (Fig. 3, C andD). The pd1EGFP is a
destabilized form of GFP with a half-life of ;1 h, mini-
mizing the time lag between changes in mRNA and protein
expression. Thus, one set of model parameters reproduces
faithfully both the dynamics of uptake and dynamics of in-
hibition, suggesting that we have captured the essential rela-
tionship between these processes in the model.
The time course of target mRNA inhibition was explored
further for the base case parameters in Fig. 4. In addition,
a set of model simulations was performed in which each of
the model parameters was allowed to vary randomly in the
range of 10% or 20% of the base case value. This variation in
parameters did not change appreciably the time course of the
antisense effect, but it did result in a modest variability in the
extent of inhibition at any time. Since the kinetic rate
parameters and numbers of species (e.g., target mRNA
molecules) is likely to vary to this extent, a distribution of
inhibition levels is expected to occur. Indeed, we observed
a substantial spreading of ﬂuorescence levels in the ﬂow
cytometry of antisense-inhibited CHO-pd1EGFP cells (data
not shown). The range depicted in Fig. 4 is the maximum
variation observed over 100 simulation runs. The standard
error would be considerably less but would require efﬁcient
sampling over the high-dimensional space spanned by the
parameters.
As expected from their effects on cytoplasmic levels, bulk
concentration of oligonucleotide has only a modest effect on
the maximum extent and dynamics of antisense inhibition
observed (Fig. 5 A), whereas endosomal escape has a more
FIGURE 2 Effect of model parameters on cytoplasmic concentrations. (A)
Effect of bulk oligonucleotide on cytoplasmic concentration, Ac. Curves
correspond to bulk concentrations (Ab) of f200, 400, 600, 800, and 1000g
nM. (B) Effect of endosomal escape rate on Ac. Curves correspond to escape
rate constants (kt) of f0.001, 0.003, 0.010, and 0.030g min1.
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signiﬁcant effect (Fig. 5 B). The time of maximum inhibition
did not vary beyond the range of 210–240 min for any bulk
concentration or endosomal escape rate tested. The oligo-
nucleotide-mRNA hybridization rate and the oligonucleotide
stability exhibited the most profound inﬂuences on antisense
activity. Under the normal range observed experimentally for
hybridization rate (see Table 1), outputs vary from no anti-
sense effect to substantial effect (Fig. 6). When the half-life
of the ON is very short (;20 min), the model predicts that
little inhibition will be observed, regardless of hybridization
rate (Fig. 6 A). For an ON half-life on the order of hours,
the association rate between ON and target mRNA dictates
the extent of inhibition but does not signiﬁcantly affect the
timescale over which inhibition occurs (Fig. 6 B). A very
stable ON (half-life;40 h) could result in extended duration
of inhibition; however, a sufﬁciently fast hybridization rate
would still be required (Fig. 6 C).
The intracellular half-lives of phosphodiester (PO) ONs
have been estimated to be tens of minutes and those of PS
ONs on the order of several hours, with some variation
depending on delivery method and cell type (16). Thus, Fig.
6, A and B, corresponds to our expectations for PO and PS
ONs, respectively. We can compare these predictions to
experiments quantifying the levels of the rat gp130 mRNA
targeted by fast binding and slow binding antisense PS ONs
(9). The dynamics of inhibition and their dependence on
binding rate match well the predictions of the model (Fig. 6
D, cf. Fig. 6 B). The fact that the model describes accurately
both the magnitude and dynamics of inhibition, as the critical
FIGURE 3 Interplay of uptake and
activity dynamics. (A) Predicted differ-
ence in cytoplasmic concentration of a
fast binding (ka ¼ 10.0 mM1 min1)
versus nonbinding (ka ¼ 0) oligonucle-
otide. Base case parameters were used
in the model except for a cytoplasmic
degradation rate of 0.003 min1. (B)
Experimental results for uptake of
ﬂuorescently labeled oligonucleotides
that are complementary (A-ODN157) or
noncomplementary (A-ODNcontrol) as
a function of time after delivery to
CHO-pd1EGFP cells, as determined by
ﬂow cytometry. (C) Predicted dynamics
of antisense activity for the same param-
eter set as in A. (D) Experimentally
determined geometric mean pd1EGFP
ﬂuorescence as determined by ﬂow cyto-
metry for treatment of the same samples
analyzed in B for the complementary
oligonucleotide A-ODN157. Experimen-
tal values shown are mean 6 SE, with
the error bars in D being mostly smaller
than the symbols.
FIGURE 4 Effect of random variation in model parameters on predictions.
The antisense activity (change in target mRNA levels) was simulated for the
base case parameters and is shown in the solid line. The values of all model
parameters were each varied randomly within 10% (dotted lines) or 20%
(dashed lines), and the range of mRNA dynamics resulting from 100 runs are
shown.
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parameter of hybridization association rate is varied, testiﬁes
to the utility of the model in understanding antisense effects
at the cellular level.
It is generally assumed that a major factor in the
effectiveness of AS ONs is the recruitment of Rnase H to
ON-mRNA duplexes, followed by cleavage of the target
mRNA. As the concentration of ON-mRNA duplexes should
be always signiﬁcantly less than the Michaelis constant (17),
we employ a pseudo-ﬁrst-order expression for Rnase H
cleavage (Eqs. 6, 8, and 9). The effect of the Rnase H
cleavage rate on maximum antisense inhibition was rela-
tively minor, both at low (Fig. 7 A) and high (Fig. 7 B) rates
of hybridization. The time of maximum inhibition was only
slightly affected, ranging 225–270 min for ka ¼ 1.0 mM1
min1 and 195–255 min for ka ¼ 10.0 mM1 min1.
Finally, we studied the predicted effect of mRNA copy
number and stability on antisense effectiveness. The steady-
state (i.e., in the absence of antisense administration) mRNA
level is the ratio of the synthesis rate to the decay rate of the
mRNA. For a given mRNA copy number, the effectiveness
of antisense inhibition will depend on the stability of the
mRNA, with rapidly turned over mRNA species resulting in
lower levels and shorter durations of inhibition (Fig. 8 A). As
a corollary, if the synthesis rate is held constant and the
decay rate is varied, lower copy number transcripts are more
difﬁcult to inhibit, as they more rapidly regenerate their
FIGURE 6 Interplay of hybridization
rate and stability on antisense activity.
(A) Predicted mRNA dynamics as a
function of hybridization rate for (A)
unstable (dm ¼ 0.03 min1), (B) mod-
erately stable (dm ¼ 0.003 min1), and
(C) very stable (dm ¼ 0.0003 min1)
oligonucleotides. In each case (A–C),
the hybridization rate constants are ka¼
f0.1, 1.0, and 10.0g mM1 min1. (D)
Experimentally observed dynamics,
measured using real-time polymerase
chain reaction of the rat gp130 mRNA
in H35 cells treated with PS (moderate
stability) oligonucleotides selected for
fast binding and slow binding, respec-
tively.
FIGURE 5 Effect of bulk concentra-
tion and trafﬁcking on antisense inhibi-
tion. The minimum target mRNA levels,
normalized to the initial values, as a
function of (A) bulk oligonucleotide con-
centration and (B) endosomal escape
rate. In both cases, the minima occurred
at times between 210 and 240 min.
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steady-state mRNA level (Fig. 8 B). However, for a set of
transcripts with comparable half-lives, the level and dynam-
ics of inhibition are relatively insensitive to copy number
(not shown).
DISCUSSION
Our model builds upon previous mathematical models of
gene and oligonucleotide interactions with cells. The com-
partmentalization of DNA being delivered to a cell has been
considered in previous models of nonviral gene transfer
(14,18,19). It is generally assumed that trafﬁcking among
compartments occurs via ﬁrst-order processes. As a conse-
quence, these barriers control to a considerable extent the
time required for a biological effect and the efﬁciency of the
process. Previous models of antisense effects focused on the
mechanisms (Rnase H versus various modes of steric
hindrance) in antisense activity and on the correspondence
between down-regulation at the mRNA level and at the
protein level (5–7). Our model combines the elements of
uptake, trafﬁcking, hybridization, and catalysis to provide
a comprehensive, systems-level framework for antisense
activity at the cellular level.
Estimates for the parameters in the model are taken from
the accumulated AS ON literature. The cellular events—up-
take, trafﬁcking, and degradation—have all been monitored
in a variety of experiments but typically not all simulta-
neously in the same cells under the same conditions.
Although the parameters used are thus from disparate ex-
perimental protocols, in most cases they should be reason-
able order of magnitude estimates. The expected range of
variability of these parameters was explored to determine
the sensitivity of antisense activity to them, both individually
to see how one parameter affects the new antisense activity
but also through random variation in each parameter (Fig. 4).
In addition, the mRNA levels were varied, as speciﬁc tran-
scripts may have abundances ranging from a few copies per
cell to;104 per cell (20). Modiﬁcations to AS ON sequence
and structure are designed to inﬂuence the kinetics of hybrid-
ization, the accessibility of the mRNA portion of ON-mRNA
duplex to Rnase H degradation, and the degradation of the
ON to nuclease digestion. Quantitative measurements of these
processes can be made in vitro and provide relatively precise
values for inclusion in the model, to the extent that the rates
of these processes in vitro correspond to those in cells.
With this mathematical framework, we can both identify
the steps most likely limiting the effectiveness of AS ONs
and evaluate the feasibility of potential molecular designs
for improving their effectiveness. AS ONs must overcome
several barriers to enter cells, gain access to the target mRNA,
and inhibit its expression. Upon reaching the cytoplasm, AS
ONs can interact with mRNA through hybridization events
that are potentially limiting, until they are compartmental-
ized, degraded, or cleared. The molecular properties of the
AS ONs inﬂuence many of the events controlling AS
FIGURE 7 Effect of Rnase H degradation on antisense activity. Minimum
mRNA levels, normalized to the initial values, as a function of the ﬁrst-order
rate constant for Rnase H-mediated target degradation, for moderate
oligonucleotide-mRNA binding (ka ¼ 1.0 mM1 min1), and for more
rapid oligonucleotide-mRNA binding (ka ¼ 10.0 mM1 min1).
FIGURE 8 Effect of mRNA decay
on antisense inhibition. (A) The mRNA
decay rate (dm) was varied with the
initial mRNA level held constant at 500
copies per cell, i.e., the mRNA synthe-
sis rate (sm) was varied correspond-
ingly. Individual curves correspond to
mRNA decay rates of f0.001, 0.003,
0.01, 0.03, and 0.1g min1. (B) The
mRNA decay rate was varied with the
mRNA synthesis rate held constant,
thus resulting in a decrease in initial
mRNA level with increasing decay rate.
Individual curves correspond to mRNA
decay rates of f0.003, 0.075, 0.03,
0.075, 0.3, and 0.75g min1.
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effectiveness, thus providing an opportunity for improve-
ment via molecular design.
For example, an oligonucleotide is a highly anionic mol-
ecule, and this is presumed to hinder entrance into the cell.
Yet, signiﬁcant quantities of ON do enter cells, achieving
intracellular concentration on the order of 10–100 nM, based
on 104–105 molecules entering a cell of volume 1 picoliter
(10,21). However, high concentrations (hundreds of nano-
molar) are required for the highest levels of uptake. The most
efﬁcient and selective uptake may be conferred by a delivery
system in which one or a few high afﬁnity (e.g., epidermal
growth factor) ligands are used to deliver a depot of oligo-
nucleotide, such as in a targeted liposome or vesicle (22–24).
Nonetheless, delivery of ONs, both in naked form and
using liposomes or polymeric delivery vectors, appears to be
saturable (10–12), and this limits the utility of increasing
bulk ON concentration as a means of improving antisense
effectiveness (Figs. 2 A and 5 A). A considerable amount of
research is being directed toward the development of carriers
that will protect DNA and shuttle it into cells. However, the
major delivery obstacles are inside the cell, particularly
escape from endosomes while avoiding routing to lysosomes
and degradation (Figs. 2 B and 5 B). As such, the design of
delivery vectors is increasingly focusing on materials that
will aid in the escape from endosomes (15,25–27).
Another factor affecting antisense activity is the stability of
the particular mRNA target. Genome-wide analyses of mRNA
decay have been conducted in some mammalian cells, and
these suggest a relatively wide distribution of transcript half-
lives in which manymRNAs are stable for hours but some are
turned over in as little as 30 min (20,28,29). This particular
range of values can have a signiﬁcant effect on the effec-
tiveness of an antisense treatment (Fig. 8), as those transcripts
with short half-lives are already ‘‘programmed’’ to maintain
their baseline levels of expression in the presence of the cell’s
natural degradation processes. As such, it is likely that those
genes that are rapidly turned over, such as ‘‘early response
genes’’ induced in inﬂammatory responses, may prove re-
calcitrant to antisense treatment.
The most easily controlled design variable of an AS ON is
its sequence. The ON sequence chosen can have a dramatic
effect on its antisense effectiveness, as many target regions
of the mRNA are thermodynamically or kinetically inac-
cessible. Experimental techniques for identifying accessible
regions of mRNA, such as oligonucleotide array hybridiza-
tion and Rnase H mapping, have emerged (30,31). Fur-
thermore, computational design approaches based on the
structure-dependent thermodynamics of ON-mRNA interac-
tion can be used to select effective AS ONs (9,32,33). As
shown by our model simulations and the experimental data
of numerous researchers, antisense activity is quite dynamic,
and thus hybridization association rate rather than equilib-
rium governs activity. However, afﬁnity is proportional to
association (‘‘on’’) rate for oligonucleotide-mRNA hybrid-
ization (17), and so algorithms that select for high afﬁnity
also select for high association rate. The measured numerical
values of association rate are such that they span a range over
which little to no activity (at low association rates) to strong
and potentially prolonged antisense activity (at high asso-
ciation rate) are predicted (Fig. 6).
The antisense molecule can also be manipulated via its
chemistry. Indeed, most efforts to improve the performance
of AS ONs have focused on chemical modiﬁcation, with
particular emphasis on nuclease resistance. As can be seen
in Fig. 6, ONs with short half-lives have no opportunity to
inhibit the target mRNA, and the duration of the antisense
effect is dependent on the ON exhibiting extended intra-
cellular stability (in conjunction with the turnover rate of the
mRNA as per previous discussion). For most therapeutic
applications, a duration of effect of at least days and pre-
ferably longer is required. As such, nuclease resistance is a
necessary condition for a strong antisense effect, but it is
not sufﬁcient because of the sensitive interplay with the hy-
bridization association rate. Thus, a major challenge is de-
signing ON chemistry with improved stability without any
signiﬁcant loss in hybridization association rate (or speci-
ﬁcity). Second- and later-generation oligonucleotides such as
29-O-methyl oligoribonucleotides, C-5 propynylated oligo-
nucleotides, and locked nucleic acids may meet these criteria
(34–36). How these modiﬁcations affect delivery and traf-
ﬁcking has been less extensively explored. Modeling frame-
works such as the one presented here can be a useful tool in
interpreting potential trade-offs among delivery, stability,
and hybridization rate.
To be useful, the model should be applicable to a wide
variety of cell types and antisense AS ONs. We speciﬁcally
studied two systems experimentally in our work. Both
utilized PS oligodeoxynucleotides, but in one case gp130
was the target mRNA in H35 rat hepatoma cells, and in the
other pd1EGFP was the target in CHO cells. A number of
parameters in the model may depend on the target and cell
type, including the mRNA level and constitutive degradation
rate, the adsorption and internalization rates, the lysosomal
sorting and endosomal escape rates, and the cytoplasmic
degradation/efﬂux rate. With this number of parameters, the
general estimation problem would require a global optimi-
zation approach (37), so we sought the simplest explanation
for cell-type differences. Based on the observed dynamics
being of longer duration in CHO cells, the cytoplasmic de-
gradation rate was the most logical candidate parameter.
Indeed, changing the value of this parameter fourfold from
the base case (which was used to simulate gp130 in H35
cells) resulted in excellent agreement for both uptake and
activity dynamics in the CHO cells. The dynamics that we
observed are in the range observed for other cell culture
systems, in which maximum inhibition may occur anywhere
from 4 h to 48 h, depending on the ON structure and cell type
(38,39). Thus, at least for these experimental systems, the
model provides a useful construct to understand cell-type
differences in antisense behavior.
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In summary, our model provides a framework for
understanding the interplay of mechanistic events in overall
antisense effectiveness. It predicted accurately the timescale
and effect of molecular and cellular parameters, including the
ON-mRNA hybridization rate and ON degradation rate, on
antisense activity. By variation of model parameters, it
shows that delivery to the cell is likely not a major barrier
to effectiveness, but trafﬁcking, hybridization, and stability
within the cell are. AS ONs can be modiﬁed primarily
through choice of sequence and ON chemistry, and our work
provides a framework for rationally designing these. With
the advent of RNA interference (RNAi), this framework
could be modiﬁed to replace ON hybridization and Rnase
H-mediated destruction of the mRNA with formation of a
RNA-induced silencing complex via short interfering RNA
followed by target mRNA degradation (40,41). Through
a systems understanding of the molecular and cellular
processes affecting the activity of oligonucleotides, both in
antisense and in RNAi, it should be possible to accelerate
their development in a variety of research and applications
areas.
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